Shanghai MicroPort Endovascular MedTech Co., Ltd. provided earnings guidance for the six months ended 30 June 2020. The net profit attributable to the equity owners of EV MedTech for the six months ended 30 June 2020 is expected to be between RMB 118 million and RMB 123 million, representing an increase of between 38.80% and 44.68% from the same period last year. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 108 million and RMB 113 million, representing an increase of between 40.44% and 46.94% from the same period last year. The increase in profit is primarily attributable to the new products launched in recent years of EV MedTech that have been steadily admitted for bidding and entered hospitals, which gradually contributed to the revenue increase of EV MedTech, and the revenue maintained a satisfactory growth trend during the reporting period. In addition, the expenses of EV MedTech have decreased against revenue during the reporting period, and EV MedTech has used part of the proceeds from its fund raising exercise and its own funds for cash management to earn interest income.